Clinical trial
Efficacy and Safety of SR46349B in Patients With Sleep Disorders in Fibromyalgia
NCT00313885 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00313885 |
|---|---|
| Title | Efficacy and Safety of SR46349B in Patients With Sleep Disorders in Fibromyalgia |
| Official title | Efficacy and Safety of SR46349B (1 and 5mg/Day) Administered During 8 Weeks in Patients With Sleep Disorders in Fibromyalgia: Multi-center, Randomized, Double-blind, Placebo-controlled Study. |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Fibromyalgia, Sleep, Chronic Pain |
| Intervention type | Drug |
| Interventions | eplivanserin (SR46349), placebo |
| Enrollment | 205 |
| Start date | Apr 1, 2004 |
| Primary completion | Jun 1, 2005 |
| Completion | Jun 1, 2005 |
| First posted | Apr 12, 2006 |
| Last update posted | Nov 30, 2010 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: